BioSpace News Archive

Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s over-allotment option to purchase 375,000 additional shares of common stock at a price to the public of $5.00 per share.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2021.

The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share

Development of low-cost LOC devices, introduction of CLIA-waived tests, and increasing global geriatric population are some key factors driving market revenue growth.

Steady shift from conventional diagnostics technology to advanced automated systems for diagnosis of diseases and growing adoption of medical imaging workstations are key factors fueling market growth.

Anji Pharma announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the program’s MCL1 inhibitors.

CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype.

Today, Olympus Corporation of the Americas announced market availability of its 510(k)-cleared Telegraph Evolution® surgical nail system from FH ORTHO, a company that Olympus acquired in November 2020.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, and AM-Pharma, an emerging leader focused on the development of therapeutics that protect organ function in patients with severe medical conditions, have signed a commercial manufacturing agreement to advance AM-Pharma’s recombinant human Alkaline Phosphatase (recAP) program towards commercialization.